NCT01699490

Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder

Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: National Cheng-Kung University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to identify evidence-based guidelines for treating major depressive disorder to full remission in Taiwanese major depressive disorder (MDD) patients. To achieve this goal, the investigators aim to: (1) evaluate the risks and benefits of adjunctive pharmacotherapies for cognitive and metabolic consequences in MDD, and (2) clarify the shared biological mechanisms between mood, immune and metabolism homeostasis

Detailed description

The prevalence of insulin resistance did not significantly differ among the healthy controls and drug-naïve MDD patients before and after antidepressant treatment. Meanwhile, the current study indicated that antidepressants might affect insulin secretion independently of the therapeutic effects on MDD. Therapeutic strategies considering both treatment effectiveness and glucose-insulin homeostasis in MDD patients are necessary.

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	Fluoxetine + Valsartan	The curative effect of fluoxetine add-on valsartan 40 mg per day for 12 weeks therapy in the treatment of major depressive disorder.
DRUG	Fluoxetine + Placebo	The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.

Timeline

• Start date: 2012-08-01
• Primary completion: 2015-07-01
• Completion: 2015-07-01
• First posted: 2012-10-03
• Last updated: 2014-09-29

Locations

1 site across 1 country: Taiwan